Cancer Letters
Volume 206, Issue 2 , Pages 193-199, 8 April 2004

The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer

Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636, USA

Received 25 July 2003; accepted 14 August 2003.

Abstract 

The importance of the IκB kinase (IKK)/NF-κB signaling pathway in immunoregulatory functions is well accepted. However, the relevance of IKK and NF-κB in tumor maintenance, tumor promotion and possibly even in tumor initiation is becoming more evident. Activation of the IKK/NF-κB signaling pathway leads to the induction of target genes that can interfere with apoptosis, cell cycle regulation, cell invasion and metastatic growth as well as radio- and chemotherapy. By possibly bridging inflammation and cancer NF-κB might also contribute to tumorigenesis. Several natural compounds and synthetic drugs that are able to inhibit the IKK/NF-κB activation pathway have been shown to either prevent cancer or to inhibit cell growth in animal models. However, these compounds do not selectively inhibit any of the NF-κB activation pathways. Furthermore, general inhibition of NF-κB might lead to immunodeficiency. The investigation of the different NF-κB signaling pathways in different cell types and their role in certain diseases is therefore needed to evaluate the most successful therapeutic strategies.

Keywords: IκB kinase, NF-κB, Cancer, Inflammation, Cell cycle, Apoptosis, Metastasis, Therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(03)00629-3

doi:10.1016/j.canlet.2003.08.029

Cancer Letters
Volume 206, Issue 2 , Pages 193-199, 8 April 2004